Clinical Trial Update: A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

A first-in-human Phase 1/2 study of EPI-321 for facioscapulohumeral muscular dystrophy is currently recruiting, sponsored by Epicrispr Biotechnologies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• EPI-321

Snippet

Sponsor: Epicrispr Biotechnologies, Inc. | Conditions: Facioscapulohumeral Muscular Dystrophy | Phase 1, Phase 2 | Status: RECRUITING